# US 2013/0280259 A1 · Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0280259 A1 - Document ID: US20130280259A1 - Status: Published application - Kind: A1 - Application number: 13/816,679 - Filed: 2011-08-12 - Published: 2013-10-24 - Earliest claimed: 2010-08-12 - Assignees: Servicio Andaluz De Salud - Inventors: Manuel Vicente Salinas Martín - Web page: https://patentgrep.com/patent/US20130280259A1 ## CPC - C07K 16/30: from tumour cells - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 37/02: Immunomodulators - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 16/286: {against neuromediator receptors, e.g. serotonin receptor, dopamine receptor} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The object of this invention is the use of an antibody or a fragment thereof specific against NK1, NK2 and/or NK3 receptors of cells, for the manufacture of a medicament for the therapeutic management of human cancer, by direct administration to a mammal, including humans, by inducing cell death or apoptosis of tumour cells, modification of peritumoural microenvironment (consisting of stromal cells, stromal matrix, and intra and peritumoural vascularisation) and/or inflammatory and/or immune response around the tumour. In particular, in the case of melanoma, carcinoma (specially, breast carcinoma, lung, digestive system, prostate, cervix, endometrium, ovary and bladder), leukaemia, lymphomas, neoplasms, such as neuroblastoma and sarcoma, such as osteosarcoma. ## Claims ### Claim at position 1 -16. (canceled) ### Claim 17 A composition comprising at least one antibody or fragment thereof specific against NK1, NK2 and/or NK3 receptors, or combinations thereof. ### Claim 18 (depends on 17) The composition according to claim 17 wherein the antibody recognises at least a sequence of NK1, NK2 and/or NK3 receptors, comprising a species selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO: 3. ### Claim 19 (depends on 17) The composition according to claim 17 which further comprises carriers and/or pharmaceutically acceptable vehicles. ### Claim 20 (depends on 17) A method for the treatment of cancer that comprises administering (i) an antibody or fragment thereof specific against NK1, NK2 and/or NK3 receptors, or combinations thereof, or (ii) a composition of claim 17 to a patient. ### Claim 21 (depends on 20) The method according to claim 20 wherein the cancer is selected from the group comprising: melanoma, gliomas, carcinomas, adenocarcinomas, leukaemias, neoplasms of embryonic or neuroectodermic type and/or sarcomas. ### Claim 22 (depends on 21) The method according to claim 21, characterised in that the carcinoma comprises a species selected from the group consisting of any of the following: breast, lung, thyroid, prostate, cervix, endometrium, ovary, bladder, and choriocarcinoma. ### Claim 23 (depends on 21) The method according to claim 21, characterised in that the adenocarcinoma comprises a species selected from the group consisting of any of the following: colon, breast, ovary, pancreas, lung, and gastric. ### Claim 24 (depends on 21) The method according to claim 21, characterised in that the leukaemia comprises a species selected from the group consisting of: T cell lymphoblastic, B cell lymphoblastic, and T/NK cell leukaemia. ### Claim 25 (depends on 21) The method according to claim 21, characterised in that the lymphoma comprises a species selected from the group consisting of: type B, type T, Hodgkin's lymphoma, and Burkitt's lymphoma. ### Claim 26 (depends on 21) The method according to claim 21, characterised in that the sarcomas are osteosarcomas, rhabdomyosarcomas, endometrial stromal sarcomas, fibrosarcomas, malignant fibrous histiocytoma, or Edwing sarcoma. ### Claim 27 (depends on 21) The method according to claim 21, characterised in that the neoplasms are neuroblastomas or retinoblastomas. ### Claim 28 (depends on 17) A method for the induction of apoptosis in tumour cells that comprises administering (i) an antibody or fragment thereof specific against NK1, NK2 and/or NK3 receptors, or combinations thereof, or (ii) a composition of claim 17 to a patient. ### Claim 29 (depends on 17) A method for the reduction of tumour size that comprises administering (i) an antibody or fragment thereof specific against NK1, NK2 and/or NK3 receptors, or combinations thereof, or (ii) a composition of claim 17 to a patient. ### Claim 30 (depends on 29) The method according to claim 29, characterised in that the reduction of tumour size is performed by modifying the peritumoural microenvironment. ### Claim 31 (depends on 30) The method according to claim 30 characterised in that the modification of the peritumoral microenvironment comprises the modification of the physiology of the stromal matrix and the stromal cells and/or the modification of the physiology of cells involved in inflammatory and immune response and/or the modification of the physiology of the cells responsible for vascularisation. ### Claim 32 (depends on 31) The method according to claim 31 characterised in that the modification of the physiology of the stromal matrix and stromal cells and/or the modification of physiology of the cells involved in the inflammatory and immune response comprises the inhibition of tumour markers. ### Claim 33 (depends on 32) The method according to claim 32 wherein the tumour markers comprise a species selected from the group consisting of any of the following list: NF-kB, TGF alpha, TGF-beta 1, TGF-beta 2, TGF-beta 3, SPARC, MMP-3, MMP-7, MMP-9, MMP-11, MMP-13, MMP-14, and any combinations thereof. ### Claim 34 (depends on 31) The method according to claim 31 characterised in that the modification of the physiology of the cells responsible for vascularisation comprises the inhibition of neovascularisation by inhibiting the proliferation of vascular endothelial cells.